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for <1% of sCJD cases. the atypical nature of the cases is also reflected in the illness duration: the mean duration of nine of the sCJD cases was 12.2 months, and a further two cases were alive at over 17 months. the mean duration of sCJD in most countries is around 4.5 months, and correlates with various independent factors, including PRNP genotype and prion protein type.
7 the atypical nature of the group studied by lodi et al. calls into question the generalizability of their conclusions.
a substantially larger and more disease typerepresentative study of mri was pub lished shortly after the lodi et al. study. Zerr at al. evaluated mri findings in 436 patients with sCJD and 141 controls. 4 using pre specified criteria based on caudate-putamen and cerebral cortical signal changes on fluidattenuated inversion recovery and Dwi sequences, the re searchers found positive mri results in 83% of cases. the proportions of PRNP 129 genotypes in this study-62.7% mm, 18.6% mv and 18.6% vv-were more representative of the sCJD population as a whole than were those in the lodi et al. study. on the basis of their results, Zerr et al. propose a modification of the current clinical diagnostic cri teria to include these mri ab normalities as su pportive findings. 4 any treatments that are developed for prion disease are likely to be most effective early in the disease process, necessitating prompt diagnosis. an understanding of the timing of emergence of mri abnormalities in relation to the disease course is, there fore, important. in the lodi et al. study, mri was undertaken at a mean of 8 months into the disease (median 6 months), partly reflecting the atypically long durations of their cases. in the Zerr et al. study, mri was undertaken at a median of 2.7 months of illness, but this is still over halfway into the average sCJD illness. mri might, therefore, not provide diagnostic support in the very early disease phase, when treatment is likely to be most useful. naturally, in a clinical context, mri is undertaken only when appreciable symptomatic brain illness emerges, making it difficult to discover whether useful mri changes are occurring at an earlier disease stage.
Cerebral imaging in prion disease has come a long way over the past few years. initially, imaging was largely a matter of excluding other possible diagnoses. one especially fortunate finding was that vCJD is associated with a striking mri abnor mality in the form of the 'pulvinar sign' , 2 and an important role for mri in the diagnosis of the more common sCJD is now emerging. underlying this progress is the develop ment of morepowerful mri machines and new mri sequences (such as Dwi). these developments inevitably bring problems, such as the necessity to compare data from equivalent mri machines and questions of standardization of methods.
lodi et al. reported unique findings with regard to 1 Hmrs, an mri technique and PICALM-which exert modest effects on aD risk, but show strong correlation with aD risk when all available data are combined. notably, the most prominent result in both studies was the association between aD risk and the clusterinencoding CLU gene, which is located on the short arm of chromo some 8. owing to its functional relationship with apolipoprotein e (APOE), CLU (also known as apolipoprotein J) was previously studied as a candidate gene in aD. these earlier studies, which probed for a poten tial association between CLU and aD risk, however, lacked power due to insufficient sample sizes and other methodo logical issues, precluding earlier recognition of this locus as an aD risk gene. numerous studies utilizing conventional genetic linkage and positional cloning experiments have revealed that mutations in the genes encoding amyloid precursor protein, presenilin 1 and presenilin 2 can lead to altered production of aβ, which is sufficient to cause rare, earlyonset (~50 years of age) familial forms of aD. the vast majority of aD cases, however, are of later onset (>65 years of age), and this latter form of aD is widely believed to be influenced by an array of lowpenetrance, common risk alleles. these alleles prob ably affect a variety of pathways, many of which are believed to be involved in the production, aggregation and removal of aβ. although the total number of aD risk genes (and their precise identity) remains unclear, good evidence exists to suggest that, in combination, these genes have a substantial impact on disease pre disposition and age of onset. in the search for these lateonset aD genetic risk factors, hundreds of loci have been assessed in well over 1,200 genetic association studies. a common misconception in the field is that, overall, these studies have not yielded any consistent results besides the discovery of an association between the APOE ε4 allele and aD. in fact, over 30 different loci have been identified that seem, on systematic metaanalysis of the available data, to be associated with aD risk (for an uptodate overview, see the 'alzGene' database 4 ). the novel genes highlighted in the recent studies by lambert et al. and Harold et al. could, therefore, be thought merely to extend this list by three additional loci. 2, 3 several charac teristics, however, set these new studies apart from most other previous aD genetic studies. as a result, CLU, CR1 and PICALM are placed high on the current 'top results' list on alzGene, which ranks aD genetic studies according to a combina tion of criteria, including effect size, P value, degree of heterogeneity, and assessment for reporting biases. 4 First, and most importantly, CLU, CR1 and PICALM were identified as risk factors for aD by means of a genomewide associ ation approach. Gwas simultaneously probe hundreds of thousands of genetic markers, in an essentially unbiased and hypothesisfree manner. the fact that both novel Gwas independently found CLU to be associated with increased aD risk is particularly interesting, given the vast number of genetic markers that were assessed. second, the overarching theme of pre vious genetic association studies in complex diseases has been the lack of inde pendent replica tion. in view of the prob able small effect sizes exerted by any one of these loci, the inconsistencies might be at least partially explained by a lack of power due to insufficient sample size of the indivi dual studies. lambert et al. and Harold et al. overcame this limitation by combin ing large data sets for both their initial genomewide analyses and the followup genotyping. the twostage Gwas con ducted by lambert and colleagues involved nearly 15,000 participants from europe, and the study conducted by Harold et al. included a similar number of individuals (>16,000) from europe and the us. in addi tion, both studies have already provided independent replication for each other's main findings, although only CLU showed genomewide significant associ ation within each study individually. third, additional independent replication of the new Gwas results for two of the three novel loci, CR1
and PICALM, was actually already (and unknowingly) provided by previously published aD Gwas. [5] [6] [7] last, when all the available genetic evidence is classified using recently proposed guidelines for the cumu lative assessment of genetic association data, all three loci show strong epidemio logical credibility, a characteristic shared by only half a dozen other loci on the alzGene 'top results' list.
CLU has long been considered to be a can didate gene for aD and, accordingly, a wealth of functional data has accrued over the past 15 years. on the basis of these data, the leading hypothesis proposes that clusterin, a 75 kDa chaperone protein that is expressed at high levels in the brain, binds to and pro motes the clearance of aβ, a function poten tially shared with APOE. APOE is believed to aid the export of aβ out of the brain into plasma; clusterin, however, is also believed to aid the reentry of aβ back into the brain. excessive re entry would be predicted to lead to enhanced aβ levels in the brain, effectively impairing its clearance. 
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news & views quite modest. indeed, these effects are more than an order of magnitude lower than the effect of the APOE ε4 allele on aD risk. Further studies will be needed to clarify the functional basis of these associations. only after this objective is accomplished can we be sure that we have identified novel aD risk genes. identification of novel aD risk genes is necessary if we are to improve our capacity for early prediction and, hopefully, prevention of this devastating disease.
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